Catheter PrecisionVTAK
VTAK
About: Catheter Precision Inc is engaged in design, manufacture and sale of new and innovative medical technologies primarily focused in the field of cardiac electrophysiology, or EP. The Company's primary product is the View into Ventricular Onset System (VIVO or VIVO System), which is a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. The VIVO system has achieved a CE Mark allowing it to be commercialized in the European Union and has been placed at several hospitals in Europe. Its newest product, the Surgical Vessel Closing Pressure Device (LockeT), is a suture retention device indicated for wound healing by distributing suture tension.
Employees: 22
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
400% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 1
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
25% more funds holding
Funds holding: 8 [Q4 2024] → 10 (+2) [Q1 2025]
1.34% more ownership
Funds ownership: 6.0% [Q4 2024] → 7.34% (+1.34%) [Q1 2025]
7% less capital invested
Capital invested by funds: $217K [Q4 2024] → $202K (-$14.4K) [Q1 2025]
Research analyst outlook
We haven’t received any recent analyst ratings for VTAK.
Financial journalist opinion
Based on 3 articles about VTAK published over the past 30 days
Neutral
GlobeNewsWire
3 days ago
Catheter Precision, Inc. Comments on Recent Market Activity
FORT MILL, S.C., June 12, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE American: VTAK), a U.S.-based innovative medical device company focused on electrophysiology products, is issuing this press release in response to recent increases in trading activity in its common stock. The Company is not aware of any information related to the Company or its operations that it would have expected to cause increased market activity. The Company continues to pursue its strategic plans as previously disclosed, including its ongoing efforts to secure financing to meet its liquidity needs.
Neutral
MCAP MediaWire
2 weeks ago
Catheter Precision, Inc. Receives CE Mark for LockeT
FORT MILL, S.C., May 27, 2025 – PRISM MediaWire – Catheter Precision, Inc. (NYSE American: VTAK), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market announced that it has received CE Mark approval for LockeT, the latest advanced vascular closure device.
Neutral
GlobeNewsWire
2 weeks ago
Catheter Precision, Inc. Receives CE Mark for LockeT
Opens Multi-Billion Market Opportunity for the Company First Order for 100 Units Received FORT MILL, S.C., May 27, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE American: VTAK), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market announced that it has received CE Mark approval for LockeT, the latest advanced vascular closure device.
Neutral
GlobeNewsWire
1 month ago
Catheter Precision, Inc. Announces $1.5 Million Private Placement Equity Financing and Potential Strategic Alliance
Fort Mill, S.C., May 12, 2025 (GLOBE NEWSWIRE) -- Catheter Precision (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market, today announced that it has entered into securities purchase agreements with institutional investors for a $1.5 million private placement equity financing and the acquisition of certain promissory notes of QHSLab, Inc.
Neutral
GlobeNewsWire
1 month ago
Catheter Precision Makes NYSE American Section 610(b) Public Announcement
Fort Mill, S.C., April 17, 2025 (GLOBE NEWSWIRE) -- -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market, announced today that, as previously disclosed in its Annual Report on Form 10-K for the year ended December 31, 2024, filed March 31, 2025, with the Securities and Exchange Commission, the audited financial statements contained an audit opinion from its independent registered public accounting firm that included a Substantial Doubt Regarding Going Concern paragraph. See further discussion in footnote 1 to the Company's consolidated financial statements included in the Company's Annual Report on Form 10-K.
Neutral
GlobeNewsWire
2 months ago
Catheter Precision, Inc. Announces Fourth Quarter and Full Year 2024 Update and Financial Results
FORT MILL, S.C., March 28, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE American: VTAK), a U.S.-based innovative medical device company focused on electrophysiology products, today announced its financial results and operational update for the period ending December 31, 2024.
Neutral
GlobeNewsWire
4 months ago
Catheter Precision Inc. Engages PCG Advisory to Broaden Investor Relations Strategy
BRIDGEWATER, N.J., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Catheter Precision Inc. (NYSE American: VTAK) (“Catheter Precision” or the “Company”), a U.S.-based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market, today announced its engagement with PCG Advisory, a leading investor relations, strategic communications, and digital strategies firm, to enhance investor outreach and communication efforts.
Neutral
MCAP MediaWire
4 months ago
Catheter Precision Inc. Engages PCG Advisory to Broaden Investor Relations Strategy
BRIDGEWATER, NJ, February 10, 2025 – PRISM MediaWire – Catheter Precision Inc. (NYSE American: VTAK) (“Catheter Precision” or the “Company”), a U.S.
Neutral
GlobeNewsWire
4 months ago
Catheter Precision to Attend and Participate in the 13th Internation Symposium on Left Atrial Appendage
FORT MILL, S.C., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market announced their attendance at the 13th International Symposium on Left Atrial Appendage (ISLAA). ISLAA will take place on February 7th and 8th, 2025 in Austin, Texas.
Neutral
GlobeNewsWire
4 months ago
Catheter Precision, Inc. Announces The Closing of its Acquisition of PeriKard, LLC
FORT MILL, S.C., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE American: VTAK), a U.S.-based innovative medical device company focused on electrophysiology products, today announces that it has closed the previously announced acquisition of PeriKard, LLC.
Charts implemented using Lightweight Charts™